Logo
x

Search

Subscribe Now

Moderate-To-Severe

Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-Severe Asthma

Regeneron and Sanofi's Dupixent (dupilumab) Receive the US FDA's Approval as an Add-On Maintenance Treatment to Treat Moderate-To-...

  • October 21, 2021
Sanofi's Dupixent (dupilumab) Receives Health Canada Approval as the First Biologic to Treat Atopic Dermatitis in Children

Sanofi's Dupixent (dupilumab) Receives Health Canada Approval as the First Biologic to Treat Atopic Dermatitis in Children

  • February 24, 2021
LEO Pharma Receives the US FDA's Fast Track Designation for Delgocitinib Cream to Treat Moderate-to-Severe Chronic Hand Eczema

LEO Pharma Receives the US FDA's Fast Track Designation for Delgocitinib Cream to Treat Moderate-to-Severe Chronic Hand Eczema

  • August 5, 2020
Sanofi's Dupixent (dupilumab) Receives the US FDA's Approval as First Biologic for Children Aged 6-11 Years with Moderate-to-Severe Atopic Dermatitis

Sanofi's Dupixent (dupilumab) Receives the US FDA's Approval as First Biologic for Children Aged 6-11 Years with Moderate-to-Sever...

  • May 27, 2020
Eli Lilly's Taltz (ixekizumab) Receives the US FDA's Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Eli Lilly's Taltz (ixekizumab) Receives the US FDA's Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaq...

  • March 30, 2020
Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthritis

Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthri...

  • March 2, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.